Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ERAS Stock Forecast 2025-2026
$1.27
Current Price
$359.77M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ERAS Price Targets
+766.1%
To High Target of $11.00
+293.7%
To Median Target of $5.00
+175.6%
To Low Target of $3.50
ERAS Price Momentum
-8.6%
1 Week Change
+8.5%
1 Month Change
-31.4%
1 Year Change
-49.4%
Year-to-Date Change
-63.2%
From 52W High of $3.45
+25.7%
From 52W Low of $1.01
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Erasca (ERAS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ERAS and similar high-potential opportunities.
Latest ERAS Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ERAS has a bullish consensus with a median price target of $5.00 (ranging from $3.50 to $11.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.27, the median forecast implies a 293.7% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Evercore ISI Group, projecting a 766.1% upside. Conversely, the most conservative target is provided by Chris Shibutani at Goldman Sachs, suggesting a 175.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ERAS Analyst Ratings
8
Buy
0
Hold
0
Sell
ERAS Price Target Range
Low
$3.50
Average
$5.00
High
$11.00
Current: $1.27
Latest ERAS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ERAS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $6.00 |
| Mar 26, 2025 | Raymond James | Laura Prendergast | Outperform | Initiates | $5.00 |
| Mar 21, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $6.00 |
| Mar 21, 2025 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $3.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $4.00 |
| Jan 7, 2025 | B of A Securities | Alec Stranahan | Buy | Upgrade | $5.00 |
| Nov 18, 2024 | Jefferies | Maury Raycroft | Buy | Initiates | $6.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $6.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $6.00 |
| Oct 25, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $3.50 |
| Aug 14, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $3.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $6.00 |
| May 28, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $4.00 |
| May 20, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Maintains | $5.00 |
| May 9, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $8.00 |
| Apr 2, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $7.00 |
| Mar 28, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $8.00 |
| Mar 11, 2024 | Capital One | Naureen Quibria | Overweight | Initiates | $8.00 |
| Jan 5, 2024 | B of A Securities | Alec Stranahan | Neutral | Downgrade | $6.00 |
| Nov 29, 2023 | Mizuho | Mara Goldstein | Buy | Maintains | $7.00 |
Erasca Inc. (ERAS) Competitors
The following stocks are similar to Erasca based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Erasca Inc. (ERAS) Financial Data
Erasca Inc. has a market capitalization of $359.77M with a P/E ratio of -1.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -45.8%.
Valuation Metrics
Market Cap
$359.77M
Enterprise Value
$106.00M
P/E Ratio
-1.9x
PEG Ratio
-1.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+84.6%
Current Ratio
12.4x
Debt/Equity
12.7x
ROE
-45.8%
ROA
-22.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Erasca Inc. (ERAS) Business Model
About Erasca Inc.
What They Do
Develops precision oncology therapies for cancer.
Business Model
Erasca Inc. operates as a clinical-stage biopharmaceutical company, generating revenue through the development of innovative cancer treatments that target specific genetic mutations. The company focuses on creating investigational drugs that address unmet medical needs and aims to advance these candidates through strategic partnerships and collaborations, which enhance its research capabilities and speed up clinical trials.
Additional Information
Based in San Diego, California, Erasca is dedicated to transforming cancer treatment and improving patient outcomes by leveraging cutting-edge molecular biology techniques. Its commitment to precision medicine positions it as a key player in the life sciences sector, with a robust pipeline aimed at multiple cancer types.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
103
CEO
Dr. Jonathan E. Lim M.D.
Country
United States
IPO Year
2021
Website
www.erasca.comErasca Inc. (ERAS) Latest News & Analysis
Latest News
Quick Summary
Erasca, Inc. (Nasdaq: ERAS) reports strong progress with its RAS-targeting drugs, expecting Phase 1 data by 2026. The company has $411 million in cash, extending its runway to H2 2028.
Why It Matters
Erasca's robust cash position and successful IND approvals for new therapies position it well for future growth, potentially boosting investor confidence and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Erasca, Inc. (Nasdaq: ERAS) received FDA clearance for ERAS-0015 and submitted an IND for ERAS-4001. Cash runway extended to H2 2028 due to partnership strategy for naporafenib.
Why It Matters
Erasca's IND clearance for two promising cancer therapies boosts investor confidence, suggesting potential market leadership and extended financial stability through 2028.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Erasca, Inc. (Nasdaq: ERAS) will present at the Bank of America Securities 2025 Health Care Conference on May 14, 2025, at 2:35 PM PT and will hold one-on-one investor meetings.
Why It Matters
Erasca's participation in a major healthcare conference signals potential visibility and credibility, which can impact investor sentiment and share price, especially in the oncology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Erasca, Inc. presented promising preclinical data on ERAS-0015 and ERAS-4001 at the AACR meeting, highlighting their potential as best-in-class therapies targeting the RAS/MAPK pathway.
Why It Matters
Erasca's promising preclinical data on ERAS-0015 and ERAS-4001 highlights potential breakthroughs in cancer therapy, which could significantly enhance its market position and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Erasca, Inc. is developing targeted therapies for solid tumors, with lead program naporafenib showing promise in NRAS-mutant melanoma. Key phase 3 data is expected in 2025, and the company has funding until at least 2027.
Why It Matters
Erasca's promising pipeline, especially with naporafenib in NRAS-mutant melanoma and strong financial stability, positions it well for future growth and reduced dilution risk.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Erasca, Inc. (Nasdaq: ERAS) will present three posters at the AACR Annual Meeting in April 2025, showcasing potential therapies targeting the RAS/MAPK pathway.
Why It Matters
Erasca's presentations on innovative cancer therapies could boost investor confidence, signaling potential breakthroughs in a competitive oncology market and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ERAS Stock
What is Erasca Inc.'s (ERAS) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Erasca Inc. (ERAS) has a median price target of $5.00. The highest price target is $11.00 and the lowest is $3.50.
Is ERAS stock a good investment in 2025?
According to current analyst ratings, ERAS has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.27. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ERAS stock?
Wall Street analysts predict ERAS stock could reach $5.00 in the next 12 months. This represents a 293.7% increase from the current price of $1.27. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Erasca Inc.'s business model?
Erasca Inc. operates as a clinical-stage biopharmaceutical company, generating revenue through the development of innovative cancer treatments that target specific genetic mutations. The company focuses on creating investigational drugs that address unmet medical needs and aims to advance these candidates through strategic partnerships and collaborations, which enhance its research capabilities and speed up clinical trials.
What is the highest forecasted price for ERAS Erasca Inc.?
The highest price target for ERAS is $11.00 from Josh Schimmer at Evercore ISI Group, which represents a 766.1% increase from the current price of $1.27.
What is the lowest forecasted price for ERAS Erasca Inc.?
The lowest price target for ERAS is $3.50 from Chris Shibutani at Goldman Sachs, which represents a 175.6% increase from the current price of $1.27.
What is the overall ERAS consensus from analysts for Erasca Inc.?
The overall analyst consensus for ERAS is bullish. Out of 12 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are ERAS stock price projections?
Stock price projections, including those for Erasca Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 2:01 PM UTC